Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Apixaban for Treatment of Embolic Stroke of Undetermined Source (ATTICUS Randomized Trial)

Next Previous
Search
Trial Profile

Apixaban for Treatment of Embolic Stroke of Undetermined Source (ATTICUS Randomized Trial)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 09 Oct 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apixaban (Primary) ; Aspirin
  • Indications Stroke
  • Focus Therapeutic Use
  • Acronyms ATTICUS

    • Most Recent Events

    • 28 Aug 2023 Results assessing the overall atrial fibrillation burden in the ATTICUS cohort; to determine the correlation between AF detection and new ischemic lesions; and to explore predictors for atrial fibrillation within the enriched ESUS population, presented at the ESC Congress 2023 - Annual Congress of the European Society of Cardiology.
    • 10 Feb 2023 Primary endpoint (Imaging Endpoint: Occurrence of at least one new ischemic lesion at 12 months after study drug initiation when compared to baseline MRI before study drug initiation) has not been met, as per presented at the International Stroke Conference 2023.
    • 10 Feb 2023 Results of subgroup analysis assessing (n=352) the efficacy of apixaban, initiated within 28 days after ESUS versus acetylsalicylic acid in preventing new ischemic lesions on 12-month follow- up MRI (primary endpoint) in subjects with remote atrial fibrillation (AF) monitoring, presented at the International Stroke Conference 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top